U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519265) titled 'Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets' on March 20.
Brief Summary: This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.
Study Start Date: July 09, 2026
Study Type: INTERVENTIONAL
Condition:
T2DM (Type 2 Diabetes Mellitus)
Intervention:
DRUG: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1
Fixed-dose combination tablet containing chigl...